… pharmaceutical excipient that has been approved by the FDA … the clinical translation of drugs and medical nanomaterials. Through active … in treatment of triple-negative breast cancers. Int Pharmaceut. 2019 … for co-delivery of paclitaxel and rapamycin for breast …

… that a Phase 3 trial has met its secondary endpoint … 1 antibody, in combination with paclitaxel-based chemotherapy, with or … PD-L1-expressing tumors. Treatment with Keytruda showed a statistically … an immune checkpoint inhibitor treatment has shown a benefit …

… treatments for this condition for a long time.” HERCULES Findings The trial … Center for Personalized Medicine, Einstein Hospital Israelita … regimens — such as paclitaxel, ifosfamide, and cisplatin … international randomized multicenter trials. Given the rarity …

… in patients with claudication. Paclitaxel-coated vs. uncoated … participant-masked randomized clinical trials were embedded in the … coated devices groups used paclitaxel. Drug-coated devices did not … a strategy trial rather than a device trial. This might …

… of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine in … LEAP-014 Trial? The LEAP-014 trial enrolled patients … 5-flourouracil (FP) or paclitaxel plus cisplatin (TP) … drug discontinuation occurred in 33.3% of patients. Treatment- …

… trial (NCT05427383) presented at the 2025 European Society for Medical … rest receiving a taxane (paclitaxel or docetaxel). At data … . TEAEs that led to treatment discontinuation were reported in 10 … HRs for anbenitamab justify trials comparing it to other …

… phase III trial of Enhertu followed by paclitaxel, trastuzumab and … from four major pivotal trials at this year’s … strategy to bring novel treatments to early cancer settings … , and commercialisation of prescription medicines in oncology, rare diseases, …

… four major pivotal trials in particular, new … trial of trastuzumab deruxtecan, marketed as Enhertu, either followed by paclitaxel … broader range of medicines, including cancer treatments (3). … imported branded or patented pharmaceutical products (4). References …

… trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel … Dubberke, MD, Professor of Medicine, Clinical Director, Transplant Infectious … to date in clinical trials of different cancers, … and immunosuppressive barrier to cancer treatment; (2) SYN-004 ( …

… la Sociedad Europea de Oncología Médica (ESMO 2025) y … abierto, aleatorizado de nab-paclitaxel y gemcitabina con o sin … R. Dubberke, profesor de Medicina, director clínico de Enfermedades Infecciosas … del Trasplante, Facultad de Medicina de la Universidad de …